References
- Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63:892-909
- Weiden PJ, Kozma C, Grogg A, et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004;55:886-91
- Velligan DI, Diamond PM, Mintz J, et al. The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia. Schizophr Bull 2008;34:483-93
- Knapp M, King D, Pugner K, et al. Non-adherence to antipsychotic medication regimens: associations with resource use and costs. Br J Psychiatry 2004;184:509-16
- Valenstein M, Copeland LA, Blow FC, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 2002;40:630-9
- Ascher-Svanum H, Faries DE, Zhu B, et al. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 2006;67:453-60
- Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv 2001;52:805-11
- Velligan DI, Weiden PJ, Sajatovic M, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 2009;70(4 Suppl):1-46
- Weissman MM, Verdeli H, Gameroff MJ, et al. National survey of psychotherapy training in psychiatry, psychology, and social work. Arch Gen Psychiatry 2006;63:925-34
- Chue P, Emsley R. Long-acting formulations of atypical antipsychotics: time to reconsider when to introduce depot antipsychotics. CNS Drugs 2007;21:441-8
- Abilify [package insert]. Tokyo, Japan: Otsuka Pharmaceutical Co, Ltd, 2009. http://www.abilify.com/pdf/pi.aspx?q=aripiprazole+prescribing+information&ie=utf-8&oe=utf-8&aq=t&rls=org.mozilla:en-US:official&client=firefox-a. Accessed August 3, 2010
- Seroquel [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP, 2010. http://www1.astrazeneca-us.com/pi/Seroquel.pdf. Accessed August 3, 2010
- Risperdal [package insert]. Raritan, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc, 2010. http://www.risperdal.com/sites/default/files/shared/pi/risperdal.pdf. Accessed August 3, 2010
- Zyprexa [package insert]. Indianapolis, IN: Eli Lilly and Company, 2010 http://pi.lilly.com/us/zyprexa-pi.pdf. Accessed August 3, 2010
- Geodon [package insert]. New York, NY: Roerig Division of Pfizer, 2009. http://media.pfizer.com/files/products/uspi_geodon.pdf. Accessed August 3, 2010
- Hwang W, Weller W, Ireys H, et al. Out-of-pocket medical spending for care of chronic conditions. Health Aff (Millwood) 2001;20:267-78
- Karve S, Cleves MA, Helm M, et al. An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients. Med Care 2008;46:1125-33
- Gardner W, Mulvey EP, Shaw EC. Regression analyses of counts and rates: poisson, overdispersed poisson, and negative binomial models. Psychol Bull 1995;118:392-404
- Agresti A. Categorical data analysis. Hoboken, NJ: John Wiley & Sons, Inc., 1990
- Holm S. A simple sequentially rejective Bonferroni test procedure. Scand J Statist 1979;6:65-70
- Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. Br Med J 1999;319:1492-5
- Dolder CR, Lacro JP, Leckband S, et al. Interventions to improve antipsychotic medication adherence: review of recent literature. J Clin Psychopharmacol 2003;23:389-99
- Hendryx MS, Russo JE, Stegner B, et al. Predicting rehospitalization and outpatient services from administration and clinical databases. J Behav Health Serv Res 2003;30:342-51
- Olfson M, Mechanic D, Hansell S, et al. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 2000;51:216-22